Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

323results about How to "Low immunogenicity" patented technology

Anti-CD3 nano antibody capable of activating T cell activity as well as preparation method and application of anti-CD3 nano antibody

The invention belongs to the field of molecular biology and immunology, and particularly relates to an anti-CD3 nano antibody capable of activating the activity of T cells as well as a preparation method and application of the anti-CD3 nano antibody. The invention provides a preparation method of the anti-CD3 nano antibody. The preparation method comprises the following steps: constructing a CD3 plasmid and an overexpression cell line, and immunizing alpaca to obtain peripheral blood mononuclear cells (PBMC) of the alpaca; extracting RNA (Ribonucleic Acid) and carrying out reverse transcription to obtain cDNA; carrying out PCR amplification on the antibody gene segment and cloning the antibody gene segment to a phage display vector; and electrically transforming the vector into SS320 competent cells to obtain the nano antibody library. After two rounds of panning, detecting and screening an antibody clone capable of being combined with the CD3 protein through ELISA (Enzyme-Linked Immunosorbent Assay); an antibody sequence is selected through sequencing, and an antibody protein is expressed by using a mammalian cell high-throughput expression system; and then detecting and screening the antibody which is only specifically combined with the CD3. The method disclosed by the invention is simple, convenient and rapid to operate, and can be used for preparing active antibodies for treating potential tumors and proliferative diseases.
Owner:BIOINTRON BIOLOGICAL INC

Recombinant human-derived II-type collagen, nucleic acid molecule, carrier, cell, composition and application of recombinant human-derived II-type collagen, nucleic acid molecule, carrier, cell and composition

The invention discloses a recombinant human-derived II-type collagen, a nucleic acid molecule, a carrier, a cell, a composition and application thereof, and relates to the technical fields of genetic engineering and synthetic biology. The recombinant human-derived II-type collagen comprises a calcium ion binding domain and has an effect of promoting osteoblast proliferation, so that the recombinant human-derived II-type collagen has a good application prospect in preparation of medical instruments and compositions. The recombinant human II-type collagen provided by the invention can be expressed in a common expression system, and has the advantages of high expression quantity and no endotoxin hidden danger. Moreover, the recombinant human II-type collagen does not carry purification labels such as histidine labels and the like, and can be purified through a molecular sieve, so that the target protein can be directly obtained finally, and the purification labels such as the histidine labels and the like do not need to be additionally cut off. The production method of the recombinant human-derived II-type collagen is suitable for industrial large-scale production, and the prepared product does not have an animal-derived infection source, so that the biological safety is higher.
Owner:XIAN GIANT BIOGENE TECH CO LTD +1

Humanized nano antibody targeting cadherin 17 and application thereof

The invention relates to a humanized nano antibody targeting cadherin 17 and application of the humanized nano antibody, and relates to the technical field of immunology and molecular biology. The complementarity determining region of the humanized nano antibody comprises a CDR1 of which the amino acid sequence is shown as SEQ ID NO: 2, a CDR2 of which the amino acid sequence is shown as SEQ ID NO: 4 and a CDR3 of which the amino acid sequence is shown as SEQ ID NO: 6; a framework region of the humanized nano antibody comprises an FR1 of which the amino acid sequence is shown as any one of SEQ ID NO: 1 and SEQ ID NO: 8, an FR2 of which the amino acid sequence is shown as any one of SEQ ID NO: 3, SEQ ID NO: 9 and SEQ ID NO: 11, an FR3 of which the amino acid sequence is shown as any one of SEQ ID NO: 5 and SEQ ID NO: 10, and an FR4 of which the amino acid sequence is shown as SEQ ID NO: 7. According to the humanized nano-antibody, the immunogenicity of the nano-antibody is reduced, the targeted binding activity and killing activity are improved, and the humanized nano-antibody can be used for developing immunodetection reagents, CAR-T / NK cell drugs and antibody drugs.
Owner:BEIJING ROCK EDGE BIOTECHNOLOGY CO LTD

Recombinant XVII type collagen with triple helix structure and application of recombinant XVII type collagen

The invention provides a recombinant XVII type collagen with a triple helix structure, and belongs to the technical field of biological proteins. The amino acid sequence of the collagen comprises one or more amino acid residue repetitive units, each repetitive unit comprises a sequence as shown in SEQ ID NO.1 or SEQ ID NO.2, the number of repetitions is n, and n is larger than 1 and smaller than or equal to 60. The recombinant XVII type collagen provided by the invention is simple in production process, relatively high in expression quantity, low in immunogenicity, high in safety, relatively good in stability of the triple-helix structure, and strong in supporting capacity for skin cells; efficacy experiments show that the collagen has higher cell adhesion, wound healing promotion and hair follicle repair promotion capability than XVII type collagen products in the market at present, and can be widely applied to the fields of food, health care products, cosmetics, medical instruments and the like.
Owner:BLOOMATURE BIOTECHNOLOGY CO LTD

Transparent decellularized biological material as well as preparation method and application thereof

The invention relates to the technical field of biological materials, and particularly discloses a transparent acellular biological material as well as a preparation method and application thereof. The transparent decellularized biological material provided by the invention is prepared from animal membrane tissues, and the thickness of the transparent decellularized biological material is 1-500 microns; the light transmittance is 89.10% to 95.05%, the breaking strength is 6.21 N to 50.95 N, and the sewing strength is 2.24 N to 25.60 N. The biological material disclosed by the invention is high in transparency and good in strength, can be used in the field of repairing biological patch materials with relatively high requirements on transparency degree, and is wide in application prospect.
Owner:ABORIMEI (CHENGDU) MEDICAL TECH CO LTD

Bacterial surface modification method based on atom transfer radical polymerization reaction mediation, modified bacteria and application of modified bacteria

The invention discloses a bacteria surface modification method based on atom transfer radical polymerization reaction mediation, obtained bacteria and application. The modification method comprises the following steps: carrying out acryloylation on the surfaces of the bacteria by using N-hydroxysuccinimide acrylate, and introducing double bonds on the surfaces of the bacteria to obtain acryloylated bacteria; the method comprises the following steps: by taking acrylamide, N-(3-aminopropyl) methacrylamide hydrochloride and N, N '-methylene bisacrylamide as monomers, carrying out polymerization reaction on the surfaces of acrylated bacteria in the presence of an initiator and a catalyst; the mass ratio of the acrylamide to the N-(3-aminopropyl) methacrylamide hydrochloride to the N, N '-methylene bisacrylamide is (11.9 to 17.5) to (0.125 to 1) to (0.1 to 0.5). According to the method, bacteria can be camouflaged to reduce immunogenicity and pathogenicity of the bacteria, the safety of bacteria treatment is improved under the condition that the viability and multiplication capacity of the bacteria are not affected, the resistance of the bacteria to environmental threats is enhanced, and the bacteria are endowed with no exogenous functions.
Owner:ANHUI MEDICAL UNIV

Preparation method and application of manganese-based amino acid coordination polymer

The invention discloses a preparation method and application of a manganese-based amino acid coordination polymer, and belongs to the technical field of nano-enzymes and nano-drugs. Divalent manganese salt, histidine and other amino acids are subjected to a co-precipitation reaction to prepare the manganese-based amino acid coordination polymer, and the polymer is of a nanoparticle structure, small in size and high in stability, has enzyme-like activity, catalyzes hydrogen peroxide to generate high-toxicity hydroxyl free radicals and is used for specifically killing tumor cells. The catalyst has the capability of catalytically generating singlet oxygen in the presence of hydrogen peroxide. Meanwhile, the manganese-based amino acid complex has glutathione oxidase-like activity, consumes glutathione to overcome the resistance of tumors to oxidative stress, improves the chemical kinetic curative effect, and has anti-tumor application potential.
Owner:CHANGZHOU UNIV

Artificial exosome and application thereof in drug delivery

The invention relates to the technical field of medicine, and discloses an artificial exosome and application thereof in drug delivery, the artificial exosome is prepared into an oil phase based on PLGA and DOTAP, and a water phase based on OCT4 protein and siTrim28; mixing the two phases to obtain a primary emulsion, and adding a PVA aqueous solution to obtain a double emulsion; stirring the double emulsion and volatilizing the solvent to form an emulsified solution, and centrifuging to obtain PLGA nanoparticles; the lipid mixture is prepared from lipid, DPPE-PEG2000, alpha-tocopherol and alpha-lactalbumin, and a lipid film is formed after a solvent is evaporated; the preparation method comprises the following steps: mixing PLGA nanoparticles, a lipid film and membrane protein, uniformly mixing and heating to obtain a film-coated solution, and finally extruding through a cellulose acetate film to obtain the artificial exosome. The artificial exosome disclosed by the invention combines the stability of the PLGA nanoparticles and the biocompatibility of the lipid membrane, and provides new possibility for a drug delivery system.
Owner:GUANGZHOU MEDICAL UNIV +1

Nano-carrier for gene editing of aquatic animals and gene editing method

The invention discloses a nano-carrier for gene editing of aquatic animals. The nano-carrier comprises a) TNP nano-particles and b) Cas9 mRNA and sgRNA. The invention also discloses an application of the TNP nano-particle as an mRNA delivery carrier and a gene editing method based on the nano-carrier, according to the method, the TNP nano-particle with good biocompatibility is used for packaging Cas9 mRNA and sgRNA, and an efficient and low-damage gene editing delivery mode is realized. The nano-carrier is delivered into an embryo of an aquatic animal in a non-invasive manner, so that the transfection efficiency and the specificity of gene editing are optimized. In addition, the method can improve the gene editing efficiency and precision and enhance the embryo survival rate, is simple, convenient and safe to operate and wide in applicability, can support customized gene editing, and is beneficial to promoting the application of gene editing in aquatic product germplasm genetic improvement.
Owner:SOUTH CHINA SEA FISHERIES RES INST CHINESE ACAD OF FISHERY SCI +1

Alpaca-derived nano antibody specifically bound with simian vacuolar virus 40 large T antigen and application of alpaca-derived nano antibody

The invention belongs to the technical field of molecular biology and immunology, and provides an alpaca-derived nano antibody specifically bound with a simian vacuolar virus 40 large T antigen SV40LTA and application of the alpaca-derived nano antibody. The invention relates to a heavy chain antibody, which has a heavy chain variable region VHH, the VHH comprises the following CDR: CDR1 with an amino acid sequence as shown in SEQ ID NO: 1, CDR2 with an amino acid sequence as shown in SEQ ID NO: 2, and CDR3 with an amino acid sequence as shown in SEQ ID NO: 3, the VHH comprises four frame regions of FR1-4, and FR1, FR2, FR3 and FR4 and CDR1, CDR2 and CDR3 are arranged in a staggered manner in sequence. The antibody is high in neutralizing activity and strong in binding capacity with SV40LTA, and the equilibrium dissociation constant is less than 0.1 nM; the monoclonal antibody has the advantages that the monoclonal antibody can effectively recognize SV40LTA, the molecular weight is small, the immunogenicity is small, the solubility and stability are better, and the CDR region is longer; and a potential application value is provided for SV40LTA detection.
Owner:JUNYAN BIOTECHNOLOGY (SHANXI) CO LTD

Preparation method of recombinant collagen nano-composite hydrogel for repairing wound infected by multiple drug-resistant bacteria

The invention discloses a preparation method of recombinant collagen nano-composite hydrogel for repairing wounds infected by multiple drug-resistant bacteria, which comprises the following steps: binding copper porphyrin pi-pi on titanium carbide nanosheets to form MXene coated CuTCPP nanoparticles, and carrying out amidation reaction on 3-aminophenylboronic acid and recombinant collagen to obtain the recombinant collagen nano-composite hydrogel for repairing wounds infected by multiple drug-resistant bacteria. MXene coated CuTCPP is doped into a modified recombinant collagen system and mixed with a polyvinyl alcohol solution, and the recombinant collagen nano-composite hydrogel is prepared. The self-healing property endowed by the dynamic cross-linking characteristic of the phenylboronic acid ester bond in the composite hydrogel disclosed by the invention can be highly adapted to irregular wounds; the nano particles with the heterojunction structure can be combined with photothermal therapy and photodynamic therapy to efficiently sterilize wounds; the hydrogel has the antibacterial property and the property of promoting wound healing, and can comprehensively and efficiently treat wounds infected by multiple drug-resistant bacteria.
Owner:NORTHWEST UNIV

Nucleic acid aptamer-based covalent lysosome targeting chimera and application thereof in protein degradation and immunotherapy

The invention discloses a covalent lysosome targeting chimera based on a nucleic acid aptamer and application of the covalent lysosome targeting chimera in protein degradation and immunotherapy, and belongs to the technical field of biology. The invention designs a covalent lysosome targeting chimera with click chemical reaction activity, and the simple and efficient covalent lysosome targeting chimera is used for realizing efficient protein degradation at the levels of cells and living bodies. When the tool is used for targeted degradation of immunotherapy biomarkers, immunogenic apoptosis of tumor cells can be caused, so that killing of an immune system to tumors is more efficiently activated. Meanwhile, the covalent lysosome targeting chimera overcomes the problem of immune-related side effects confronted by existing antibodies and polysaccharide peptide drugs, and can effectively avoid the potential occurrence risk of the immune-related side effects while efficiently degrading the target protein.
Owner:刘庄

Construction method and application of modified AAV-8 serotype for retina wide targeting and expression

The invention belongs to the technical field of gene engineering and biology, discloses a modified adeno-associated virus AAV-8 serotype for retina wide targeting and expression, and further relates to construction and application of the modified type. 10 amino acid sequences as shown in SEQ ID NO.3 are inserted between the 590th amino acid and the 591th amino acid of an AAV-8 serotype capsid protein sequence as shown in SEQ ID NO.2, the first, second and tenth amino acids are protected amino acids, and the third to ninth amino acids are amino acid sequences obtained by screening. The modified serotype disclosed by the invention is stronger in fluorescence effect after infection and can be obviously and intuitively observed, an exogenous gene can be widely and efficiently expressed in a specific targeted tissue retina whole region, and the expression efficiency is greatly improved under the condition of using the same virus amount. And compared with a wild serotype, the serotype has better and wider targeted tissue expression and less non-targeted tissue expression.
Owner:SHANGHAI OPHTHAL-BRIGHT BIOMEDICINE TECH

Humanized antibody design device and method based on CDR transplantation and computer readable storage medium

The invention discloses a device and a method for designing a humanized antibody based on CDR transplantation, and a computer readable storage medium. The method comprises the following steps: replacing an antigen complementarity determining region sequence of a humanized antibody sequence with an antigen complementarity determining region sequence of a target antigen heterologous antibody to obtain a CDR region transplantation antibody; the method comprises the following steps: performing single amino acid reverse mutation on different amino acid sites of a CDR region transplantation antibody and a heterologous antibody, and comparing structural difference scores of protein three-dimensional structures before and after mutation; retaining the single amino acid reverse mutation site with the structural difference score less than or equal to 1, and finally obtaining the CDR transplanted humanized antibody of the target antigen. According to the method, the similarity of heterologous antibody and human antibody sequences can be increased, the immunogenicity of the target antigen human antibody is reduced, and the affinity is maintained.
Owner:BIOINTRON BIOLOGICAL INC

Recombinant VI-type collagen as well as preparation method and application thereof

The invention discloses a recombinant VI-type collagen as well as a preparation method and application thereof. The recombinant VI-type collagen comprises a protein gene segment derived from a natural VI-type collagen alpha2 chain, and proteins P0607, P060702 and / or P060703 capable of promoting cartilage cell proliferation activity are expressed. Gene segments derived from a natural type VI collagen alpha2 chain are integrated through a genetic engineering means, sequence optimization and repetition are carried out on the gene segments to enhance the biological activity of the collagen, the recombinant type VI collagen P0607, P060702 and P060703 can be stably and efficiently produced, the recombinant collagen has the effect of promoting chondrocyte proliferation, and the recombinant collagen can be applied to the field of cartilage cell proliferation. An efficient and reliable biological manufacturing way is provided for research, development and production of osteoarthritis medicines.
Owner:NORTHWEST UNIV

Genetically engineered exosome as well as slow release method and application thereof

The invention discloses a gene engineering exosome and a slow release method and application thereof, the gene engineering exosome is derived from human adipose-derived stem cells, si-tgfbr2 is loaded in the gene engineering exosome, the si-tgfbr2 is specific siRNA aiming at a Tgfbr2 gene, and the gene engineering exosome can regulate and control proliferation of VSMCs, inhibit transformation of the VSMCs from a contraction phenotype to a synthetic phenotype when the VSMCs are stimulated, and inhibit the growth of the VSMCs. According to the present invention, the gene engineering exosome can be used to maintain the normal structure and the function of the blood vessel, and the sustained release effect of the content in the gene engineering exosome can be achieved by wrapping the gene engineering exosome in the PHA biodegradable material, such that the local treatment concentration can be easily stabilized, the drug administration frequency can be easily reduced, the lasting time of the treatment effect can be easily prolonged, and the treatment gene can be effectively delivered to the target cell; the treatment effect is improved; when being used for modifying a small-caliber artificial blood vessel, the small-caliber artificial blood vessel can be improved in biocompatibility and functionality, and can be prevented from being implanted into the blood vessel for remodeling unbenign hyperplasia stenosis; the invention not only provides a new thought and method for the treatment of vascular diseases, but also has important clinical application value and popularization prospect.
Owner:FUWAI HOSPITAL CHINESE ACAD OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE

Construction and application of targeting exosome chimeric antigen receptor molecule for treating HIV (Human Immunodeficiency Virus) infection

The invention discloses construction and application of a targeted exosome chimeric antigen receptor molecule for treating HIV (human immunodeficiency virus) infection, and belongs to the technical field of biological medicines. According to the invention, the mRNA for coding the anti-HIV CAR is directionally packaged into the targeting exosome. Nanometer antibody sequences of CD3, CD4 and CD8 < + > T receptors on targeted T cells are fused to the N terminal of LAMP-2B to construct a specific targeting plasmid, so that targeting peptides are expressed on the surface of an exosome membrane, expression plasmids containing RNA binding protein L7A and exosome tag protein CD63 are constructed, and HEK293F cells are co-transfected by the expression plasmids and CAR plasmids containing C / D box to obtain the exosome loaded with CAR mRNA and targeted to the T cells. When the exosome is incubated with PBMC (peripheral blood mononuclear cells) in vitro or is transfused back into a humanized mouse body, human CAR-T cells can be constructed, and the exosome has remarkable activity of killing virus infected cells.
Owner:WUHAN UNIV OF SCI & TECH

Preparation method of DNA nano-frame-assisted monodisperse perfluorinated carbon nanoparticles and application of DNA nano-frame-assisted monodisperse perfluorinated carbon nanoparticles in fluorine nuclear magnetic imaging

ActiveCN119147751Adistinguishable from inside to outsidemodifiableSensorsDiagnostic recording/measuringActive agentA-DNA
The invention discloses a preparation method of DNA nano-frame assisted monodisperse perfluorinated carbon nano-particles and application of the DNA nano-frame assisted monodisperse perfluorinated carbon nano-particles to fluorine nuclear magnetic imaging. The preparation method comprises the following steps: introducing fluorocarbon chain modification into a DNA nano-frame structure space through hybridization complementation; the preparation method comprises the following steps: dispersing perfluorocarbon PFC in a surfactant to form a dispersion solution, co-incubating the dispersion solution and a DNA nano-frame structure modified by an introduced fluorocarbon chain, and capturing PFC particles entering a space by taking the fluorocarbon chain in the DNA nano-frame structure as a seed, so that the PFC is self-assembled in the DNA nano-frame structure to form nano-particles with uniform size, namely the nano-fluorine probe is obtained. According to the method, the PFC nano-particles are prepared by utilizing the three-dimensional DNA nano-frames (DNF) with various different structures, the method has the advantages of design controllability, uniform size and the like, and the prepared fluorine probe is single and sharp in nuclear magnetic signal and has a good application prospect.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Application of polypeptide DGEA or derivative thereof in promoting differentiation of pluripotent stem cells into mesenchymal stem cells

The invention belongs to the technical field of stem cell development and differentiation, and discloses application of polypeptide DGEA or a derivative thereof in promoting pluripotent stem cells to be differentiated into mesenchymal stem cells. The invention specifically discloses application of the polypeptide and the derivative thereof in promoting differentiation of pluripotent stem cells into pluripotent stem cells or preparing products for promoting differentiation of pluripotent stem cells into pluripotent stem cells. The amino acid sequence of the polypeptide is DGEA. The invention discloses the application of DGEA in promoting differentiation of pluripotent stem cells (embryonic stem cells, embryonic germ cells or induced pluripotent stem cells) into pluripotent stem cells (mesenchymal stem cells) for the first time, and the effect of DGEA is verified through corresponding experiments. The DGEA can obviously improve the efficiency of differentiating the embryonic stem cells, the embryonic germ cells or the induced pluripotent stem cells into the mesenchymal stem cells, and the obtained mesenchymal stem cells are high in safety and high in differentiation capacity.
Owner:FUTURE HOMO SAPIENS INST OF REGENERATIVE MEDICINE CO LTD (FHSR) +1

Drug-guided anti-inflammatory enhanced mesenchymal stem cell preparation and application of drug-guided anti-inflammatory enhanced mesenchymal stem cell preparation in improvement of osteoarthritis

The invention discloses a drug-guided anti-inflammatory enhanced mesenchymal stem cell preparation as well as a preparation method and application thereof. By constructing the medicine-loaded mesenchymal stem cell preparation, the immunosuppression capacity of the mesenchymal stem cells is improved, the angiogenesis capacity of the mesenchymal stem cells is reduced, meanwhile, by releasing the glucocorticoid medicine at a low dosage, the side effect of single administration is avoided, M2 type macrophage polarization is induced, the inflammatory state of cartilage cells is improved, and the effect of treating the cartilage cells is achieved. The curative effect of the mesenchymal stem cells on osteoarthritis is improved in multiple aspects, and the mesenchymal stem cells are proved in animal bodies. The drug-guided anti-inflammatory enhanced mesenchymal stem cell preparation provides a new thought for the treatment of osteoarthritis.
Owner:THE FIRST AFFILIATED HOSPITAL OF FUJIAN MEDICAL UNIV

Preparation of exosome and electrostatic spinning composite material for promoting bone regeneration and application of exosome and electrostatic spinning composite material in bone tissue regeneration

The invention relates to the technical field of tissue engineering, and particularly discloses preparation of an exosome and electrostatic spinning composite material for promoting bone regeneration and application of the exosome and electrostatic spinning composite material in bone tissue regeneration. Identifying the multiplication capacity, the surface marker and the multidirectional differentiation capacity of the cells after the cells are separated and cultured, and finally extracting and identifying the exosome; pLLA and gelatin are dissolved in a cosolvent trifluoroethanol, composite fibers are prepared through electrostatic spinning, and a composite fiber membrane is obtained through spinning by adopting a receiver; the exosome is loaded on the surface of the PLLA / gelatin composite fiber membrane. According to the invention, the exosome derived from human mesenchymal stem cells is combined with the membrane material to prepare the exosome capable of stably releasing, the good stability and low immunogenicity of the exosome are exerted, and the effect of accurately promoting local bone regeneration is realized. And defect repair and functional reconstruction are realized.
Owner:CHINA JAPAN FRIENDSHIP HOSPITAL +1

A mouse-derived single-chain antibody against porcine IgA and its application

The invention belongs to the field of biotechnology, and specifically relates to a mouse-derived anti-swine IgA single-chain antibody and an application thereof. The single-chain antibody comprises a heavy chain variable region and a light chain variable region, the amino acid sequence of the heavy chain variable region is shown in SEQ ID No.1, and the amino acid sequence of the light chain variable region is shown in SEQ ID No.3. The gene sequence of the mouse-derived antibody variable region is compared with the gene sequence of the prepared single-chain antibody, and the result shows that the gene sequence of the single-chain antibody is basically consistent with the gene sequence of the mouse-derived antibody variable region, proving that the constructed antibody gene sequence is correct. The single-chain antibody fills the gap of the anti-swine IgA single-chain antibody on the current market, provides new materials for the early diagnosis and prevention and control of pig-derived IgA antibodies, and provides new technical support for controlling the epidemic spread of pig diarrhea diseases as soon as possible.
Owner:LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)

Human-mouse chimeric monoclonal antibody for resisting human MOG protein and application of human-mouse chimeric monoclonal antibody

The invention belongs to the technical field of monoclonal antibody preparation, and particularly relates to a human-mouse chimeric monoclonal antibody for resisting human myelin sheath oligodendrocyte glycoprotein (MOG) and application of the human-mouse chimeric monoclonal antibody. Complementary determining regions in variable regions of a heavy chain and a light chain of the human-mouse chimeric monoclonal antibody of the anti-human MOG protein come from a mouse, parent activity is reserved to the maximum extent, a constant region is a human antibody constant region, immunogenicity is greatly reduced due to introduction of the human antibody constant region, the occurrence probability of a human anti-mouse antibody reaction is reduced, and the anti-human MOG protein is prepared. The specificity of the antibody is improved. The human-mouse chimeric monoclonal antibody resisting the human MOG protein has antigen binding specificity, the heterology of a mouse monoclonal antibody is greatly reduced, the biological activity of the human-mouse chimeric monoclonal antibody is good, and the human-mouse chimeric monoclonal antibody resisting the human MOG protein can specifically detect the MOG protein.
Owner:SHAANXI MYBIOTECH CO LTD

Human-mouse chimeric monoclonal antibody of anti-human Hu protein and application of human-mouse chimeric monoclonal antibody

The invention provides an anti-human Hu protein human-mouse chimeric monoclonal antibody and application thereof, and belongs to the technical field of immunodetection. According to the anti-human Hu protein human-mouse chimeric monoclonal antibody provided by the invention, variable regions of a heavy chain and a light chain come from a mouse, the parent activity is reserved to the maximum extent, a constant region comes from a human source, and due to introduction of the human antibody constant region, the immunogenicity is greatly reduced, the occurrence probability of human anti-mouse antibody reaction is reduced, and the specificity of the antibody is improved. The human-mouse chimeric monoclonal antibody disclosed by the invention not only has antigen binding specificity, but also greatly reduces the heterology of the mouse monoclonal antibody. The chimeric antibody can recognize Hu protein, has biological activity, can be used for Hu antigen detection and other scientific researches, and has very good application value and very important scientific research guiding significance.
Owner:SHAANXI MYBIOTECH CO LTD

Engineered extracellular vesicle, preparation method, application and drug for targeted repair of blood brain barrier

The invention belongs to the technical field of biological medicine, and provides an engineered extracellular vesicle, a preparation method, application and a drug for targeted repair of blood brain barrier in order to solve the technical problems that an existing repair tool takes effect slowly and is not enough in specificity, and the engineered extracellular vesicle is loaded with Wnt7a-K190A protein. After entering the brain, the engineered extracellular vesicle can be rapidly and specifically combined with a Gpr124 receptor to promote blood brain barrier repair, and in-vivo experiments verify that the engineered extracellular vesicle can promote blood brain repair, so that the engineered extracellular vesicle can be applied to preparation of targeted blood brain barrier repair drugs, becomes a supplement of existing tools, AAV, LNP and the like, and has a wide application prospect. Particularly, the high requirement on the treatment timeliness of central nervous system (injury irreversibility) diseases is met.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV

Method for preparing RNA (Ribonucleic Acid) through in-vitro transcription and application

The invention discloses a method for preparing RNA (Ribonucleic Acid) through in-vitro transcription and application. The method comprises the following steps: (1) preparing a linearized DNA template; (2) constructing an in-vitro transcription reaction system, and performing in-vitro transcription under a reaction condition suitable for transcription; and (3) purifying the prepared mRNA. According to the method, RNA polymerase can reduce 3 '-extension and non-specific transcription initiation of an IVT product under the condition that the temperature is increased, and an appropriate amount of L-arginine or salt thereof is added into a reaction system, so that the RNA structure can be effectively prevented from being damaged while the mRNA yield is not reduced, and the generation of dsRNA is further reduced. In addition, the reduction of dsRNA can significantly reduce the immunogenicity of mRNA.
Owner:TRICISION BIOTHERAPEUTICS (ZHUHAI) INC

Dietary protein-derived antioxidant peptide HYHE and application thereof

The invention relates to the technical field of antioxidant peptides, in particular to an antioxidant peptide HYHE derived from dietary protein and application of the antioxidant peptide HYHE. The amino acid sequence of the antioxidant peptide is HYHE and is as shown in SEQ ID NO: 1. The antioxidant peptide is obtained based on prediction of an antioxidant peptide prediction platform Pred5AOP; 27 dietary proteins are virtually hydrolyzed through trypsin and pepsin, and the antioxidant peptide HYHE is screened out; compared with chemical drugs, the antioxidant peptide HYHE serving as the biological peptide has the advantages of high stability, low immunogenicity, high purity and the like; meanwhile, the invention further proves that the dietary protein has rich nutritional value, provides a new thought for resource recycling, and has good social and economic benefits.
Owner:JILIN UNIVERSITY

Locally anticoagulant acellular bone matrix composite material and preparation method thereof

The invention relates to the technical field of biological materials, in particular to a local anticoagulation acellular bone matrix composite material and a preparation method thereof.The preparation method comprises the following steps that S1, bone tissue is obtained and treated, and an acellular bone matrix is prepared; s2, mixing an anticoagulant with the acellular bone matrix to form an anticoagulant compound; s3, mixing the anticoagulant compound with a biocompatible carrier to form a final composite material; and S4, preparing the composite material into an implant or a stent with a required shape through a molding and curing process. By arranging the acellular bone matrix, the natural structure and biological activity of the bone matrix are reserved to the maximum extent, and meanwhile, all cell components are removed, so that immunogenicity and pathogen transmission are reduced; by adding the anticoagulant, discomfort can be reduced after the local anticoagulant acellular bone matrix composite material is implanted into a human body, and the problems that in the prior art, an acellular bone matrix has the blood coagulation risk, and incompletely-treated bone tissue has immunological rejection are solved.
Owner:FIRST HOSPITAL AFFILIATED TO GENERAL HOSPITAL OF PLA

Composite nanomaterial and preparation method and application thereof, and composite biological nanomaterial and preparation method and application thereof

The invention relates to the technical field of biology, and discloses a composite nanomaterial and a preparation method and application thereof, and a composite biological nanomaterial and a preparation method and application thereof. The composite nano-material contains chitosan and nano-hydroxyapatite, the composite nano-material has a porous structure, and in the unit volume of the nano-material, the number of pores with the pore diameter of 50-100 microns accounts for 15-25%, the number of pores with the pore diameter of 50-100 microns accounts for 10-20%, and the number of pores with the pore diameter of 50-100 microns accounts for The ratio of the number of the pores with the pore diameter of 100-150 microns is 35-50%; the ratio of the number of the pores with the pore diameters of 150-200 microns is 5-18%; and the number of the pores with the pore diameter of more than 200 microns accounts for 10-23%. The composite nano material can control the release of the stem cell exosome while loading the stem cell exosome, so that the exosome quickly reaches an effective concentration, the rejection occurrence rate is reduced, and the treatment effect is improved.
Owner:NANJING NORMAL UNIVERSITY